Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Common Equity (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Common Equity for 10 consecutive years, with $32.6 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 166.3% to $32.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $32.6 million through Dec 2025, up 166.3% year-over-year, with the annual reading at $32.6 million for FY2025, 166.3% up from the prior year.
  • Common Equity for Q4 2025 was $32.6 million at Akebia Therapeutics, down from $41.6 million in the prior quarter.
  • The five-year high for Common Equity was $213.9 million in Q1 2021, with the low at -$50.4 million in Q3 2024.
  • Average Common Equity over 5 years is $27.3 million, with a median of $15.4 million recorded in 2022.
  • The sharpest move saw Common Equity tumbled 684.78% in 2023, then surged 190.18% in 2025.
  • Over 5 years, Common Equity stood at $74.0 million in 2021, then tumbled by 92.93% to $5.2 million in 2022, then crashed by 684.78% to -$30.6 million in 2023, then plummeted by 60.82% to -$49.2 million in 2024, then soared by 166.3% to $32.6 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $32.6 million, $41.6 million, and $29.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.